Genetic Technologies Limited
Genetic Technologies Limited (GENE) Financial Performance & Income Statement Overview
Review Genetic Technologies Limited (GENE) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Genetic Technologies Limited (GENE) Income Statement & Financial Overview
Explore comprehensive income reports for Genetic Technologies Limited GENE, broken down by year and quarter.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $4.80M | $3.96M | $4.53M | $4.15M |
| Cost of Revenue | $2.004M | $5.94M | $5.76M | $5.70M |
| Gross Profit | $2.80M | -$1.98M | -$1.22M | -$1.55M |
| Gross Profit Ratio | $0.58 | -$0.50 | -$0.27 | -$0.37 |
| R&D Expenses | $362996.00 | $389758.00 | $722851.00 | $558306.00 |
| SG&A Expenses | $5.90M | $3.71M | $3.65M | $4.11M |
| Operating Expenses | $6.27M | $3.18M | $3.36M | $3.85M |
| Total Costs & Expenses | $8.27M | $9.12M | $9.11M | $9.55M |
| Interest Income | $29645.00 | $89866.00 | $140414.00 | $79747.00 |
| Interest Expense | $38769.00 | $12853.00 | $13643.00 | $15872.00 |
| Depreciation & Amortization | $254222.00 | $280665.00 | $346396.00 | $330187.00 |
| EBITDA | -$5.47M | -$6.13M | -$5.94M | -$5.06M |
| EBITDA Ratio | -$1.14 | -$1.55 | -$0.93 | -$1.22 |
| Operating Income | -$3.47M | -$5.16M | -$4.58M | -$5.39M |
| Operating Income Ratio | -$0.72 | -$1.30 | -$1.01 | -$1.30 |
| Other Income/Expenses (Net) | -$2.13M | -$1.26M | -$1.72M | -$216850.00 |
| Income Before Tax | -$5.60M | -$6.42M | -$6.30M | -$5.61M |
| Income Before Tax Ratio | -$1.17 | -$1.62 | -$1.39 | -$1.35 |
| Income Tax Expense | $0.00 | -$5.00 | -$10316.00 | -$148013.00 |
| Net Income | -$5.60M | -$6.42M | -$6.29M | -$5.46M |
| Net Income Ratio | -$1.17 | -$1.62 | -$1.39 | -$1.31 |
| EPS | -$0.04 | -$0.05 | -$0.20 | -$0.17 |
| Diluted EPS | -$0.04 | -$0.05 | -$0.20 | -$0.17 |
| Weighted Avg Shares Outstanding | $149.02M | $120.79M | $3.22M | $3.22M |
| Weighted Avg Shares Outstanding (Diluted) | $149.02M | $120.79M | $3.22M | $3.22M |
The company's financials show resilient growth, with revenue advancing from $4.15M in Q2 2023 to $4.80M in Q4 2024. Gross profit remained healthy with margins at 58% in Q4 2024 compared to -37% in Q2 2023. Operating income hit -$3.47M last quarter, sustaining a consistent -72% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$5.47M. Net income rose to -$5.60M, while earnings per share reached -$0.04. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan